To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy

S M Yin; D L Li

doi:10.1016/j.stem.2024.10.009

To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy

Cell Stem Cell. 2024 Nov 7;31(11):1557-1559. doi: 10.1016/j.stem.2024.10.009.

Authors

S M Yin¹, D L Li²

Affiliations

¹ Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
² Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China. Electronic address: [email protected].

PMID: 39515298
DOI: 10.1016/j.stem.2024.10.009

Abstract

Epitope editing is a promising strategy for protecting hematopoietic cells from eradication by immunotherapies. Recently, in Cell Stem Cell, Ji et al. applied both base editing (BE) and prime editing (PE) to alter the epitope of CD123 in hematopoietic stem cells for CAR-T therapy against acute myeloid leukemia.¹.

MeSH terms

Epitopes* / immunology
Gene Editing
Hematopoietic Stem Cells / immunology
Hematopoietic Stem Cells / metabolism
Humans
Immunotherapy* / methods
Leukemia, Myeloid, Acute / immunology
Leukemia, Myeloid, Acute / therapy

Substances

Epitopes